Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board
Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) is one of the 10 High Growth Stocks Insiders Are Buying .
On July 6, 2026, Kalaris Therapeutics, Inc. (NASDAQ:KLRS) announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. In connection with Keating's appointment, Morana Jovan-Embiricos is stepping down from the Board.
David Hallal, Chairman of the Kalaris Board of Directors, said Keating brings strategic, operational, and legal expertise across multiple therapeutic areas and development stages. Hallal also thanked Jovan-Embiricos for her service over the past year, noting her role in helping Kalaris advance TH103 and evolve as a public biotech company.
On June 15, 2026, TD Cowen analyst Tara Bancroft initiated coverage of Kalaris Therapeutics with a Buy rating and no price target. Bancroft said the company's TH103 is a "differentiated" anti-VEGF by design through more potent VEGF inhibition and retinal retention. Bancroft added that early data in wet age-related macular degeneration suggest even a single dose can achieve competitive efficacy versus the standard of care.
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) develops and commercializes treatments for prevalent retinal diseases.
While we acknowledge the potential of KLRS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy .
Sinergia Empresarial continuará el seguimiento de esta información sobre kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.
